LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*

S. Pol; M. Bourliere; S. Lucier; V. De Ledinghen; F. Zoulim; C. Dorival-Mouly; S. Métivier; D. Larrey; A. Tran; C. Hezode; J.-P. Bronowicki; D. Samuel; P. Marcellin; J.-P. Zarski; A. Minello; L. Alric; J.-C. Trinchet; P. Nahon; D. Guyader; O. Chazouillères; G. Riachi; V. Loustaud-Ratti; X. Causse; P. Mathurin; I. Hubert-Fouchard; I. Rosa; Y. Benhamou; J. Gournay; J.-J. Raabe; F. Raffi; V. Petrov-Sanchez; A. Diallo; H. Fontaine; F. Carrat

Journal Article

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*

Pol S
Bourliere M
Lucier S
et al.

Journal of Hepatology (2015) 62 S258-S259

DOI: 10.1016/s0168-8278(15)30149-5

N/ACitations

14Readers

Get full text

Abstract

applicability for this approach.

Cite

CITATION STYLE

APA

Pol, S., Bourliere, M., Lucier, S., De Ledinghen, V., Zoulim, F., Dorival-Mouly, C., … Carrat, F. (2015). LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*. Journal of Hepatology, 62, S258–S259. https://doi.org/10.1016/s0168-8278(15)30149-5

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*

Abstract

Cite

Register to see more suggestions